ANTIVIRAL THERAPY WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN NON-PERMANENTLY INCREASES BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C

被引：0
|
作者：
Klass, Dietmar M. [1 ]
Klaus, Jochen [1 ]
Guelsahin, Oguzhan [1 ]
Hartmann, Christoph [1 ]
Adler, Guido [1 ]
Fuchs, Michael [2 ]
机构：
[1] Univ Hosp Ulm, Dept Internal Med 1, Ulm, Germany
[2] Virginia Commonwealth Univ, Hepatol Sect, Div Gastroenterol, Dept Internal Med, Richmond, VA USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1350
引用
收藏
页码：926A / 926A
页数：1
相关论文
共 50 条
  • [1] Antiviral therapy with Peginterferon Alfa-2a and ribavirin does not reduce bone mineral density in patients with chronic viral hepatitis C genotype 1 infection
    Klass, Dietmar M.
    Hartmann, Christoph
    Braig, Simone
    Adler, Guido
    Fuchs, Michael
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A200 - A201
  • [2] Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin
    Redondo-Cerezo, E.
    Casado-Caballero, F.
    Martin-Rodriguez, J. L.
    Hernandez-Quero, J.
    Escobar-Jimenez, F.
    Gonzalez-Calvin, J. L.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 (06) : 1709 - 1715
  • [3] Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin
    E. Redondo-Cerezo
    F. Casado-Caballero
    J. L. Martin-Rodriguez
    J. Hernandez-Quero
    F. Escobar-Jimenez
    J. L. Gonzalez-Calvin
    [J]. Osteoporosis International, 2014, 25 : 1709 - 1715
  • [4] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C
    Rakov, NE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 259 - 260
  • [5] Sustained viral response (SVR) with Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who were non responders (NR) to Peginterferon alfa-2b and ribavirin
    Gitlin, N
    Muther, KD
    [J]. HEPATOLOGY, 2004, 40 (04) : 343A - 343A
  • [6] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C - Reply
    Fried, MW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 260 - 260
  • [7] Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients
    Zeuzem, Stefan
    [J]. JOURNAL OF HEPATOLOGY, 2008, 49 (02) : 157 - 159
  • [8] Peginterferon alfa-2a in patients with chronic hepatitis C
    Zeuzem, S
    Feinman, SV
    Rasenack, J
    Heathcote, EJ
    Lai, MY
    Gane, E
    O'Grady, J
    Reichen, J
    Diago, M
    Lin, A
    Hoffman, J
    Brunda, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23): : 1666 - 1672
  • [9] Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
    Brixner, Diana I.
    Ye, Xin
    Chu, Teng-Chiao
    Blumentals, William A.
    Hassanein, Tarek I.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (24) : 2171 - 2178
  • [10] Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin
    Rustgi, V. K.
    Esposito, S.
    Hamzeh, F. M.
    Shiffman, M. L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (05) : 433 - 440
12345